RPG Life Sciences Board Approves FY26 Audited Results, Recommends ₹24 Dividend
RPG Life Sciences approved FY26 audited standalone and consolidated financial results for the quarter ended March 31, 2026. The board recommended a dividend of ₹24 per share. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years.
The approval of financial results and dividend recommendation are significant for shareholders. The appointment of a new independent director also impacts corporate governance. However, the results themselves are not exceptionally groundbreaking, thus a medium impact.
The company reported positive financial results and recommended a dividend, which are generally viewed favorably by investors. The appointment of a new director also indicates ongoing governance and strategic development.
RPG Life Sciences Limited announced the outcome of its Board Meeting held on April 29, 2026. The Board approved the audited financial results, both standalone and consolidated, for the quarter and year ended March 31, 2026. These results received an unmodified opinion from the Statutory Auditors, as confirmed by the Chief Financial Officer.
The Board also recommended a dividend of ₹24 per equity share, representing 300% of the face value of ₹8 per share, for the financial year 2025-26. This recommendation is subject to shareholder approval at the upcoming Annual General Meeting (AGM) and will be paid/dispatched within 30 days of such approval.
Furthermore, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a term of five years, from April 29, 2026, to April 28, 2031. This appointment is also subject to shareholder approval. Dr. Samdani, a physician with over two decades of experience, is not related to any existing directors or key managerial personnel of the company.
Additionally, the Board approved an amendment to the Code of fair disclosure, internal procedures, and conduct for regulating, monitoring, and reporting of trading by designated persons. The updated code is available on the company's website. The trading window for dealing in the company's securities will open 48 hours after the declaration of the financial results.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.